UW Developing New Marijuana-Related Drug Delivery Technology

The University of Wisconsin-Madison will be working on developing new drug delivery technology that focuses solely on cannabinoids and their potential to treat varying medical conditions. Some of those conditions will be pain and inflammation. The research will be conducted for both U.S. and Canadian markets.

Revive Therapeutics focuses on research, development and commercialization of “novel treatments”, according to Investor Ideas. Leading the research will be Jess D. Reed, Ph.D. The focal points of the research will be inflammation and wound infection. Tannin-chitosan composites will be used to test these theories.

CEO of Revive, Craig Leon, said, “”We are very excited to begin the development of a novel drug delivery system to deliver cannabinoids for the potential to treat various diseases including pain and inflammation. The development of a drug delivery technology that can safely and effectively deliver cannabinoids is an important initiative for Revive as it complements our product pipeline of cannabinoid-based therapeutics and it is part of our focus on building out a proprietary intellectual property franchise that will enable us to seek commercial partnerships with medical marijuana and pharmaceutical companies.”

The product will be a transdermal patch delivery system. Combined with cannabidiol will be chitosan and tannins. The chitosan element is to help prevent blood clotting. Tannins will be included because of the antifungal, antioxidant, antibacterial and wound healing properties. Other than pain and inflammation, developing products for skin disorders is also in the works.

Dr. Reed said, “”I am very excited to begin the development of a novel drug delivery technology that will deliver cannabinoids for treating various diseases, such as pain and inflammation. The opportunities for delivering cannabinoids for unmet medical needs are numerous and I am honored to assist Revive in achieving its objectives in commercializing novel cannabinoid-based therapies.”